Sacramento, CALIFORNIA8 Active Studies

Macular Degeneration Clinical Trials in Sacramento, CALIFORNIA

Find 8 actively recruiting macular degeneration clinical trials in Sacramento, CALIFORNIA. Connect with local research sites and explore new treatment options.

8
Active Trials
7
Sponsors
1,946
Enrolling

Recruiting Macular Degeneration Studies in Sacramento

RecruitingSacramento, CALIFORNIANCT05904028

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration....

600 participants
Jaeb Center for Health Research
View Study Details
RecruitingSacramento, CALIFORNIANCT06373731

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answ...

360 participants
Stealth BioTherapeutics Inc.
View Study Details
RecruitingSacramento, CALIFORNIANCT04567303

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the Port Delivery (PD) implant in partici...

251 participants
Hoffmann-La Roche
View Study Details
RecruitingSacramento, CALIFORNIANCT05197270

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-1...

215 participants
4D Molecular Therapeutics
View Study Details
RecruitingSacramento, CALIFORNIANCT04853251

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W)....

188 participants
Genentech, Inc.
View Study Details
RecruitingSacramento, CALIFORNIANCT06722157

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan...

180 participants
Boehringer Ingelheim
View Study Details
RecruitingSacramento, CALIFORNIANCT06664502

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 int...

92 participants
EyeBiotech Ltd.
View Study Details
RecruitingSacramento, CALIFORNIANCT05626114

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related mac...

60 participants
Genentech, Inc.
View Study Details

About Macular Degeneration Clinical Trials in Sacramento

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in Americans over 50, affecting over 11 million people. Wet (neovascular) AMD involves abnormal blood vessel growth under the retina, while dry AMD involves gradual thinning of the macula and accumulation of drusen deposits. Current treatment for wet AMD relies on anti-VEGF injections (ranibizumab, aflibercept, faricimab), with newer high-dose and extended-interval formulations reducing treatment burden. For geographic atrophy (advanced dry AMD), complement inhibitors like pegcetacoplan (Syfovre) represent the first approved treatments. Clinical trials are testing gene therapies, implantable drug delivery systems, stem cell therapies, and novel targets beyond VEGF for both wet and dry AMD.

There are currently 8 macular degeneration clinical trials recruiting participants in Sacramento, CALIFORNIA. These studies are seeking a combined 1,946 participants. Research is being sponsored by Jaeb Center for Health Research, Stealth BioTherapeutics Inc., Hoffmann-La Roche and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Macular Degeneration Clinical Trials in Sacramento — FAQ

Are there macular degeneration clinical trials in Sacramento?

Yes, there are 8 macular degeneration clinical trials currently recruiting in Sacramento, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Sacramento?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Sacramento research site will contact you about next steps.

Are clinical trials in Sacramento free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Sacramento studies also compensate for your time and travel.

What macular degeneration treatments are being tested?

The 8 active trials in Sacramento are testing new therapies including novel drugs, biologics, and treatment approaches for macular degeneration.

Data updated March 2, 2026 from ClinicalTrials.gov